Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, Sept. 06, 2022 -- Inozyme Pharma, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte,... | September 6, 2022

Related Keywords

Boston ,Massachusetts ,United States ,Inozyme Pharma ,Axel Bolte ,Stefan Riley ,Matt Pera ,Joseph Schlessinger ,Demetrios Braddock ,Yale University ,Inozyme Pharma Inc ,Nasdaq ,Globenewswire Inc ,Investor Relations ,Nc Stock Exchange ,News ,Information ,Press Release ,022 ,Inozyme ,Iopharmaceutical ,Company ,Developing ,Novel ,Herapeutics ,Or ,The ,Treatment ,F ,Abnormal ,Oday ,Nnounced ,Xel Inzy Us45790w1080 ,